Key Takeaways Rapid payer alignment and regulatory shifts may accelerate adoption of Heron's therapies, driving stronger recurring revenue and long-term earnings growth than expected. Expanded care settings and strategic opportunities position Heron for broader market access, sustained top-line outperformance, and transformative, high-margin revenue streams.Read more
Key Takeaways Expanding demand for non-opioid therapies and favorable policy changes support broader market access and sustained revenue growth for core products. Operational restructuring and improved financial flexibility position the company for efficient growth, recurring product uptake, and enhanced margins.Read more
Key Takeaways Revenue growth is threatened by concentration in few products, ongoing cash burn, and external financing needs that risk future margin pressure and dilution. Regulatory and reimbursement uncertainties, pricing scrutiny, and rising competition from generics and biosimilars could limit adoption, margin gains, and long-term earnings stability.Read more
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
